Page 4 - Myovant Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Myovant science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Myovant Science Today - Breaking & Trending Today

Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer

Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , David Marek , Uneek Mehra , Juan Camilo Arjona Ferreira , Myovant Sciences Media Contact , American Society Of Clinical Oncology , Virtual Scientific Program , European Commission , Myovant Sciences , Drug Administration , Exchange Commission , Myovant Sciences Investor Contact , Sumitomo Pharma Co Ltd , Public Affairs , Corporate Communications , Myovant Sciences Inc , European Union , Sumitovant Biopharma Ltd , Chief Medical Officer , Chief Executive Officer , Clinical Oncology , New England Journal , New Drug Application , Private Securities Litigation Reform Act , Myovant Science , United States Securities ,

Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer

Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United States , David Marek , Uneek Mehra , Juan Camilo Arjona Ferreira , Myovant Sciences Media Contact , European Commission , Myovant Sciences , Drug Administration , Exchange Commission , Myovant Sciences Investor Contact , Public Affairs , European Union , Myovant Sciences Inc , Corporate Communications , Chief Medical Officer , Chief Executive Officer , New England Journal , Private Securities Litigation Reform Act , Myovant Science , United States Securities , Myovant Science Quarterly Report , Sciences Investor Contact , Business Officer , Sciences Media Contact ,

Myovant Sciences Announces European Commission Approval for

ORGOVYX® is the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in EuropeMyovant expects to secure European. ....

United States , David Marek , Uneek Mehra , Juan Camilo Arjona Ferreira , Myovant Sciences Media Contact , European Commission , Myovant Sciences , Drug Administration , Exchange Commission , Myovant Sciences Investor Contact , Public Affairs , Sumitomo Pharma Co Ltd , Corporate Communications , Myovant Sciences Inc , European Union , Sumitovant Biopharma Ltd , Chief Medical Officer , Chief Executive Officer , New England Journal , New Drug Application , Private Securities Litigation Reform Act , Myovant Science , United States Securities , Myovant Science Quarterly Report , Sciences Investor Contact , Sciences Media Contact ,

Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis

Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , United States , Effect On Other Laboratory , Myovant Sciences , European Commission , Drug Administration , Regulatory Agency , Exchange Commission , Sumitomo Pharma Co Ltd , Myovant Sciences Inc , European Medicines Agency , Committee For Medicinal Products Human Use , Sumitovant Biopharma Ltd , Supplemental New Drug Application , Boxed Warning , Sensitive Malignancies , Mood Disorders , Suicidal Ideation , Transaminase Elevations , Cholestatic Jaundice , Blood Pressure , Menstrual Bleeding Pattern , Reduced Ability , Recognize Pregnancy , Early Pregnancy Loss , Fibroid Prolapse ,

-$0.54 EPS Expected for Myovant Sciences Ltd. (NYSE:MYOV) This Quarter

Equities analysts predict that Myovant Sciences Ltd. (NYSE:MYOV – Get Rating) will announce earnings of ($0.54) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Myovant Sciences’ earnings, with the highest EPS estimate coming in at ($0.40) and the lowest estimate coming in at ($0.63). Myovant […] ....

Davidc Marek , Matthew Lang , Thomson Reuter , Russell Investments Group Ltd , Securities Exchange Commission , Zacks Investment Research , Myovant Sciences , Marshall Wace , Myovant Sciences Ltd , Cubist Systematic Strategies , Myovant Sciences Inc , Dynamic Technology Lab Private Ltd , Myovant Sciences Get Rating , Get Rating , Zacks Investment , Myovant Science , Investment Research , General Counsel Matthew Lang , Exchange Commission , Systematic Strategies , Technology Lab Private Ltd , Investments Group , Nyse Myov ,